Literature DB >> 12967942

GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics.

Jeppe Sturis1, Carsten F Gotfredsen, John Rømer, Bidda Rolin, Ulla Ribel, Christian L Brand, Michael Wilken, Karsten Wassermann, Carolyn F Deacon, Richard D Carr, Lotte Bjerre Knudsen.   

Abstract

(1) Liraglutide is a long-acting GLP-1 derivative, designed for once daily administration in type II diabetic patients. To investigate the effects of liraglutide on glycemic control and beta-cell mass in rat models of beta-cell deficiencies, studies were performed in male Zucker diabetic fatty (ZDF) rats and in 60% pancreatectomized rats. (2) When liraglutide was dosed s.c. at 150 microg kg-1 b.i.d. for 6 weeks in ZDF rats 6-8 weeks of age at study start, diabetes development was markedly attenuated. Blood glucose was approximately 12 mm lower compared to vehicle (P<0.0002), and plasma insulin was 2-3-fold higher during a normal 24-h feeding period (P<0.001). Judged by pair feeding, approximately 53% of the antihyperglycemic effect observed on 24-h glucose profiles was mediated by a reduction in food intake, which persisted throughout the study and averaged 16% (P<0.02). (3) Histological analyses revealed that beta-cell mass and proliferation were significantly lower in prediabetic animals still normoglycemic after 2 weeks treatment compared to vehicle-treated animals that had begun to develop diabetes. When the treatment period was 6 weeks, the liraglutide-treated animals were no longer completely normoglycemic and the beta-cell mass was significantly increased compared to overtly diabetic vehicle-treated animals, while beta-cell proliferation was unaffected. (4) In the experiments with 60% pancreatectomized rats, 8 days treatment with liraglutide resulted in a significantly lower glucose excursion in response to oral glucose compared to vehicle treatment. Again, part of the antihyperglycemic effect was due to reduced food intake. No effect of liraglutide on beta-cell mass was observed in these virtually normoglycemic animals. (5) In conclusion, treatment with liraglutide has marked antihyperglycemic effects in rodent models of beta-cell deficiencies, and the in vivo effect of liraglutide on beta-cell mass may in part depend on the metabolic state of the animals.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12967942      PMCID: PMC1573996          DOI: 10.1038/sj.bjp.0705397

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  49 in total

1.  beta-cell adaptation in 60% pancreatectomy rats that preserves normoinsulinemia and normoglycemia.

Authors:  Y Q Liu; P W Nevin; J L Leahy
Journal:  Am J Physiol Endocrinol Metab       Date:  2000-07       Impact factor: 4.310

2.  Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats.

Authors:  M Szayna; M E Doyle; J A Betkey; H W Holloway; R G Spencer; N H Greig; J M Egan
Journal:  Endocrinology       Date:  2000-06       Impact factor: 4.736

3.  Profiling of Zucker diabetic fatty rats in their progression to the overt diabetic state.

Authors:  G J Etgen; B A Oldham
Journal:  Metabolism       Date:  2000-05       Impact factor: 8.694

4.  Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats.

Authors:  R Perfetti; J Zhou; M E Doyle; J M Egan
Journal:  Endocrinology       Date:  2000-12       Impact factor: 4.736

5.  Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes.

Authors:  A Vella; P Shah; R Basu; A Basu; J J Holst; R A Rizza
Journal:  Diabetes       Date:  2000-04       Impact factor: 9.461

6.  Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor.

Authors:  R Burcelin; A Da Costa; D Drucker; B Thorens
Journal:  Diabetes       Date:  2001-08       Impact factor: 9.461

7.  Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells.

Authors:  J Buteau; R Roduit; S Susini; M Prentki
Journal:  Diabetologia       Date:  1999-07       Impact factor: 10.122

8.  Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration.

Authors:  L B Knudsen; P F Nielsen; P O Huusfeldt; N L Johansen; K Madsen; F Z Pedersen; H Thøgersen; M Wilken; H Agersø
Journal:  J Med Chem       Date:  2000-05-04       Impact factor: 7.446

9.  A genetic defect in beta-cell gene expression segregates independently from the fa locus in the ZDF rat.

Authors:  S C Griffen; J Wang; M S German
Journal:  Diabetes       Date:  2001-01       Impact factor: 9.461

10.  Unbiased estimation of total beta-cell number and mean beta-cell volume in rodent pancreas.

Authors:  T Bock; K Svenstrup; B Pakkenberg; K Buschard
Journal:  APMIS       Date:  1999-08       Impact factor: 3.205

View more
  45 in total

1.  Glucagon-like peptide-1 receptor signalling reduces microvascular thrombosis, nitro-oxidative stress and platelet activation in endotoxaemic mice.

Authors:  Sebastian Steven; Kerstin Jurk; Maximilian Kopp; Swenja Kröller-Schön; Yuliya Mikhed; Kathrin Schwierczek; Siyer Roohani; Fatemeh Kashani; Matthias Oelze; Thomas Klein; Sergey Tokalov; Sven Danckwardt; Susanne Strand; Philip Wenzel; Thomas Münzel; Andreas Daiber
Journal:  Br J Pharmacol       Date:  2016-08-21       Impact factor: 8.739

2.  Liraglutide prevents microvascular insulin resistance and preserves muscle capillary density in high-fat diet-fed rats.

Authors:  Weidong Chai; Zhuo Fu; Kevin W Aylor; Eugene J Barrett; Zhenqi Liu
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-07-19       Impact factor: 4.310

Review 3.  Current and novel approaches to the drug therapy of obesity.

Authors:  Jean-Philippe Chaput; Angelo Tremblay
Journal:  Eur J Clin Pharmacol       Date:  2006-08-26       Impact factor: 2.953

4.  Pancreatic safety of GLP-1-based therapeutic agents: further insights from rodent studies?

Authors:  Jens Juul Holst
Journal:  Diabetologia       Date:  2013-07-03       Impact factor: 10.122

5.  Liraglutide: a once-daily human glucagon-like peptide-1 analogue.

Authors:  G Aimaretti
Journal:  J Endocrinol Invest       Date:  2009-09       Impact factor: 4.256

Review 6.  Concise review: pancreas regeneration: recent advances and perspectives.

Authors:  Philippe A Lysy; Gordon C Weir; Susan Bonner-Weir
Journal:  Stem Cells Transl Med       Date:  2012-01-26       Impact factor: 6.940

7.  Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide.

Authors:  Lisbeth V Jacobsen; Charlotte Hindsberger; Richard Robson; Milan Zdravkovic
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

Review 8.  The evolving place of incretin-based therapies in type 2 diabetes.

Authors:  Baptist Gallwitz
Journal:  Pediatr Nephrol       Date:  2010-02-04       Impact factor: 3.714

9.  Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide.

Authors:  Anne Flint; Khalil Nazzal; Pawel Jagielski; Charlotte Hindsberger; Milan Zdravkovic
Journal:  Br J Clin Pharmacol       Date:  2010-12       Impact factor: 4.335

Review 10.  Liraglutide in the management of type 2 diabetes.

Authors:  Estela Wajcberg; Amatur Amarah
Journal:  Drug Des Devel Ther       Date:  2010-10-22       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.